Monday April 6, 2015 from 6:30 PM to 8:30 PM CDT
Add to Calendar
Registration and heavy appetizers from 6-6:30. Program begins at 6:30.
It is the policy of the Minnesota Medical Association (MMA) to ensure balance, independence, objectivity, and scientific rigor in its CME activities. To comply with the Standards for Commercial Support of the Accreditation Council for Continuing Medical Education (ACCME), the MMA requires members of the planning committee and faculty to disclose the existence of any financial interest or other relationship he/she and his/her spouse or partner has with companies whose health care products or services are discussed in an educational presentation. The requirement applies to relationships that are in place at the time of the CME activity or in the 12 months preceding the activity.
The members of the faculty and planning committee for this conference have indicated that they have no relevant financial relationships to disclose related to the content of the CME activity.
Faculty members have declared that they will uphold the MMA's standards regarding CME activities and that any clinical recommendations are based on the best available evidence or are consistent with generally accepted medical practice. Please indicate in the comments section of the evaluation form whether you detect any instances of bias toward products manufactured by commercial interests.
Accreditation Statement:The Minnesota Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Minnesota Medical Association designates this live activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Provider contact informationJaime Olson, CME Manager
jolson@mnmed.org
612-362-3744
Minnesota Medical Association
1300 Godward St NE
Suite 2500
Minneapolis, MN 55413
Learning Objectives:
On July 9, 2012, the Food and Drug Administration (FDA) approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioid medications. The Collaborative on REMS Education (CO*RE), a multidisciplinary collaboration of 10 Partners and three cooperating organizations, have designed a core curriculum based on needs assessment, practice gaps, clinical competencies, learner self-assessment, with shared tools, resources, and outcomes to meet the requirements of the FDA REMS Blueprint.
“This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see http://ce.er-la-opioidrems.com/IwgCEUI/rems/pdf/List_of_RPC_Companies.pdf for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.”